Secondary Hyperparathyroidism Due to Renal Causes
6
0
0
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
16.7%
1 terminated out of 6 trials
75.0%
-11.5% vs benchmark
33%
2 trials in Phase 3/4
100%
3 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Retrospective Analysis of Quality of Life Changes in Patients Undergoing Parathyroidectomy for End-Stage Renal Disease
Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI
A Study on Prevention Strategies for CKD-SHPT and Related Complications Based on General Vitamin D Supplementation
Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency
Pulmonary Function, Voice and Swallowing Symptoms After Parathyroidectomy
Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation.